Pantarhei Bioscience will out-license
the patented concepts to partners after acquiring feasibility data. A possible partner should be
interested to complete the clinical development and bring the product to the market.
| Project/Indication |
Current stage of development |
| Auto-immune disease (E4) |
|
| Breast cancer (E4) |
Phase II |
| Female contraception (ARC) |
Phase II/III |
| Female contraception (E4) |
Phase II |
| Ovarian cancer (ZP) |
Preclinical |
| Depression (ENSPYR) |
Preclinical |
| Male Hypogonadism (T2) |
Preclinical |
| Male Infertility (OTE-F) |
Phase II |
When you would like to receive further information,
please contact our Director
Business Development,
Eric van der Aa
phone: + 31 (0)30 69
85 023
e-mail: ea@pantarheibio.com
top |
